Adial Pharmaceuticals (ADIL) Cash from Operations (2017 - 2026)
Adial Pharmaceuticals (ADIL) posted Cash from Operations of 1612401.0 for Q1 2026, up 68.8% sequentially from 5168037.0 in Q3 2025, and down 1.7% YoY from 1640345.14 in Q1 2025.
Adial Pharmaceuticals (ADIL) Cash from Operations (2017 - 2026) Analysis & Trends
Adial Pharmaceuticals has reported Cash from Operations for 10 years, with the latest figure at 1612401.0 in Q1 2026.
- Quarterly Cash from Operations fell 1.7% year-over-year to 1612401.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 10115102.0 (up 6.59% YoY) and the FY2025 annual result came in at 6492603.0, up 6.21% from the prior year.
- Cash from Operations improved to 1612401.0 in Q1 2026 per ADIL's latest filing, from 5168037.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 841248.0 in Q4 2022 and troughed at 5468485.0 in Q3 2024.
- A 5-year average of 2250347.33 and a median of 1894446.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2024: Cash from Operations jumped 135.45% in 2022, then slumped 1249.78% in 2024.
- Over 5 years, Cash from Operations stood at 841248.0 in 2022, then slumped by 243.24% to 1204970.0 in 2023, then tumbled by 353.83% to 5468485.0 in 2024, then climbed by 5.49% to 5168037.0 in 2025, then soared by 68.8% to 1612401.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 1612401.0, 5168037.0, and 1749271.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Adial Pharmaceuticals | 29.02 Mn | 29.02 Mn | - | -6.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.61 Mn |
| Mar 31, 2026 | -1.61 Mn |
| Sep 30, 2025 | -5.17 Mn |
| Sep 30, 2025 | -5.17 Mn |
| Jun 30, 2025 | -1.75 Mn |
| Jun 30, 2025 | -1.75 Mn |
| Mar 31, 2025 | -1.59 Mn |
| Mar 31, 2025 | -1.59 Mn |
| Sep 30, 2024 | -5.47 Mn |
| Sep 30, 2024 | -5.47 Mn |
| Jun 30, 2024 | -2.15 Mn |
| Jun 30, 2024 | -2.15 Mn |
| Mar 31, 2024 | -1.63 Mn |
| Mar 31, 2024 | -1.63 Mn |
| Dec 31, 2023 | -1.20 Mn |
| Dec 31, 2023 | -1.20 Mn |
| Sep 30, 2023 | -405,139.00 |
| Sep 30, 2023 | -405,139.00 |
| Jun 30, 2023 | -1.89 Mn |
| Jun 30, 2023 | -1.89 Mn |